Ennov, a leading provider of regulatory and clinical software solutions, has secured a significant growth investment from Bregal Sagemount and Ardian. This funding aims to enhance the company's focus on AI innovation and expand its global market presence.
Headquartered in Paris, Ennov offers a comprehensive compliance platform that integrates various domains such as Regulatory, Quality, Clinical, and Pharmacovigilance. Designed to streamline complex regulatory processes, Ennov's software replaces outdated systems, allowing organizations to meet compliance requirements more efficiently. With over 25 years of experience, the company serves approximately 650 clients and has more than 500,000 users across 30 countries.
Olivier Pâris, Ennov's CEO, emphasized the importance of partnering with firms that understand the intricacies of the life sciences sector. Both Bregal Sagemount and Ardian bring valuable insights and resources to support Ennov's ambitious goals, particularly in developing AI-driven solutions. Gene Yoon from Sagemount noted the increasing complexity of regulatory workflows, highlighting the necessity for integrated systems that enhance operational efficiency.
This investment not only strengthens Ennov's capabilities but also positions it to lead in the evolving landscape of regulatory and clinical software. With the anticipated addition of board members from both investment firms, the company is set to accelerate its growth trajectory and further innovate in the life sciences sector.